

ONCOHEROES
 BIOSCIENCES

*Advancing New
 Therapies for
 Childhood Cancer*



THE INVESTMENT THESIS

Oncoheroes is focused on discovering, developing, and commercializing new therapies for children and adolescents with cancer. Only 4 pediatric cancer-specific drugs have been approved in the last 20 years. Oncoheroes offers a unique model to accelerate development of these much needed therapeutics.

DEVELOPING AND COMMERCIALIZING LIFE-SAVING PEDIATRIC ONCOLOGY DRUGS

Cancer is the leading cause of death by disease among children in the United States. With only 4 pediatric cancer-specific drugs having been approved in 20 years, one in five children with cancer will not survive. Even for those who do survive, more than 73 percent will have resulting chronic health problems.

Oncoheroes aims to drive the development of life-saving drugs in pediatric oncology. Using their unique model, they in-licensing drugs that have shown safety and some evidence to support efficacy in adult cancers, and develop them for use in specific pediatric cancers. Conducting research in rare and orphan diseases puts Oncoheroes and the drugs they license on the path for fast-track approval with the FDA, and enables them to leverage regulatory incentives in the future. In keeping with their strategy to develop a multi-asset pipeline, Oncoheroes is currently developing two assets with one ready to enter a phase Ib-II trial in rhabdomyosarcoma, a soft tissue pediatric cancer.

3 GOOD HEALTH AND WELL-BEING



DEVELOPMENTAL PROGRESS

